K. Haynes

First name

K.

Last name

Haynes

Voss, E. A., Shoaibi, A., Lai, Y. H., Blacketer, C., Alshammari, T., Makadia, R., et al. (2023). Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study. Eclinicalmedicine, 58, 101932. http://doi.org/10.1016/j.eclinm.2023.101932

View

Re, 3rd. L., Haynes, K., Ming, E. E., Ives, W., Horne, L. N., Fortier, K., et al. (2012). Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3318

View

Carbonari, D. M., Saine, M. E., Newcomb, C. W., Blak, B., Roy, J. A., Haynes, K., et al. (2015). Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3844

View

Saine, M. E., Carbonari, D. M., Newcomb, C. W., Nezamzadeh, M. S., Haynes, K., Roy, J. A., et al. (2015). Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacol Toxicol. http://doi.org/10.1186/s40360-015-0007-z

View

Re, L., Carbonari, D. M., Saine, M. E., Newcomb, C. W., Roy, J. A., Liu, Q., et al. (2017). Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2017-000400

View